Baizensel Applies for IND for Phase 1 Clinical Trial of Glioblastoma Treatment 'VT-Tri(2)-G'

[Asia Economy Reporter Kim Young-won] VigenCell announced on the 23rd that it has submitted an Investigational New Drug (IND) application for the glioblastoma treatment 'VT-Tri(2)-G' to the Ministry of Food and Drug Safety.

VT-Tri(2)-G is a treatment for glioblastoma that uses multiple antigens to overcome immune evasion mechanisms and treat tumors. Upon IND approval, a Phase 1 clinical trial will be conducted to evaluate the safety, tolerability, and efficacy of the administration.

In the Phase 1 trial, single or stepwise repeated administration of VT-Tri(2)-G will be performed on patients with recurrent glioblastoma.

VigenCell is also conducting a Phase 2 clinical trial for 'VT-EBV-N,' a treatment for NK/T-cell lymphoma, a hematologic cancer, and a Phase 1 clinical trial for 'VT-Tri(1)-A,' a treatment for acute myeloid leukemia.

Kim Tae-gyu, CEO of VigenCell, stated, "Glioblastoma is a malignant brain tumor with a high fatality rate and difficult treatment, resulting in high unmet medical needs for patients. We will sequentially proceed with the clinical trials and research and development of VT-Tri(2)-G to reduce the treatment burden for glioblastoma patients and strive to become a new alternative."

This content was produced with the assistance of AI translation services.